U.S. Markets closed

Alnylam (ALNY) Catches Eye: Stock Jumps 10.5%

Zacks Equity Research

Alnylam Pharmaceuticals, Inc. ALNY was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 27.6% in the past one-month time frame.

The stock gained following news that the U.S. Food and Drug Administration (FDA) has approved Givlaari, its treatment for acute hepatic porphyria.

The company has seen a mixed track record when it comes to estimate revisions of two increases and three decreases over the past few weeks, while the Zacks Consensus Estimate for the current quarter hasn’t been in a trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Alnylam currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Alnylam Pharmaceuticals, Inc. Price

Alnylam Pharmaceuticals, Inc. Price

Alnylam Pharmaceuticals, Inc. price | Alnylam Pharmaceuticals, Inc. Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider Alkermes plc ALKS, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ALNY going up? Or down? Predict to see what others think:Up or Down

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alkermes plc (ALKS) : Free Stock Analysis Report
 
Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.